Importance of adequate acid suppression in the management of Barrett's esophagus.
Castell
D O
DO
Katzka
D A
DA
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001471:Barrett Esophagus / Q000188:drug therapy* / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D005744:Gastric Acid / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D008840:Microfilament Proteins / Q000378:metabolism; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D002352:Carrier Proteins; D008840:Microfilament Proteins; D018809:Proliferating Cell Nuclear Antigen; C026615:villin; D064747:Lansoprazole; D009853:Omeprazole